Abstract 375P
Background
The NAME study aims at investigating whether the treatment with Navelbine, according to the metronomic principle, is superior to conventional treatment in terms of efficacy and safety. The study has the EUDRACT no: 2016-002165-63. In addition to better efficacy, preliminary studies show treatment with frequent small dosages, not only have an effect on the tumour cells, but also, an effect on the angiogenesis and the immune cells.
Methods
The NAME trial is an open randomized multicentre phase II study. We included 163 patients with HER2 normal metastatic breast cancer in Denmark from 2017-2022. Both patients with Estrogenic receptor (ER) positive and ER negative tumours were included in the study. The randomisation is between the standard Arm A, where the patients are treated with Vinorelbine (Navelbine Oralâ): 60 mg/m2 day 1 and day 8, every three weeks for the first cycle. Hereafter 80 mg/m2 in the following cycles. In the metronomic experimental Arm B, the patients receive Vinorelbine (Navelbine Oralâ): daily doses of Navelbine. The start dose is 30 mg per day. Reduction is possible.
Results
The patients were well balanced between the two arms. Median age were 68-69 years. Primarily performance status 0-1. The adverse events found in the study shows the two regimes were both well tolerated with mostly low-grade adverse events. We found a median progression free survival (PFS) in arm A of 3.9 months (95% CI 3.4-4.5) and a median PFS in arm B of 2.3 months (95% CI 1.5-3.0). The difference was non-significant (P=0.236). The median overall survival (OS) was 16.63 months (95% CI 14.66-18.61) in arm A and 15.13 months (95% CI 12.11-18.16) in arm B. Also, non-significant (P=0.355).
Conclusions
The study was conducted in order investigate metronomic chemotherapy using a randomized trial design. There was no significant difference between the two arms regarding effect. No new signals regarding safety were observed. While metronomic chemotherapy may offer certain advantages, our findings could not demonstrate any benefit, when using Navelbine in advanced breast cancer patients in this particular investigator initiated, multicentre, Danish randomised controlled trial, the NAME trial.
Clinical trial identification
EudraCT 2016-002165-63 The NAME trial.
Editorial acknowledgement
Legal entity responsible for the study
Anne Sofie Brems-Eskildsen.
Funding
Pierre Fabre, Overture's Torg 1, Plan 2 SE-19147 Sollentuna Sweden.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
384P - Disitamab vedotin (RC48) for previously treated HER2-expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single-arm, prospective phase II clinical trial
Presenter: Yun Wu
Session: Poster session 15
Resources:
Abstract
385P - A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Presenter: David Page
Session: Poster session 15
Resources:
Abstract
386P - Exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase III OptiTROP-Breast01 study of sacituzumab tirumotecan (sac-TMT) versus chemotherapy for previously treated advanced triple-negative breast cancer (TNBC)
Presenter: Yongmei Yin
Session: Poster session 15
Resources:
Abstract
387P - A prospective phase II study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients (pts) with advanced triple-negative breast cancer (TNBC)
Presenter: Tao Sun
Session: Poster session 15
Resources:
Abstract
388P - Anlotinib or bevacizumab combined with chemotherapy for the second-line HER-2 negative metastatic breast cancer: A retrospective cohort study
Presenter: jin xiang
Session: Poster session 15
Resources:
Abstract
389P - Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
Presenter: Huihui Li
Session: Poster session 15
Resources:
Abstract
390P - SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Presenter: Maria Cona
Session: Poster session 15
Resources:
Abstract
391P - Real-world activity of sacituzumab govitecan for metastatic breast cancer
Presenter: Stefania Morganti
Session: Poster session 15
Resources:
Abstract
392P - Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Adam Brufsky
Session: Poster session 15
Resources:
Abstract
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15
Resources:
Abstract